Treatment of premenstrual syndrome and premenstrual dysphoric disorders with combined oral contraceptives

Abstract

The aim of the study is to evaluate effectiveness of the OC containing drospirenone for PMS and PMDD treatment. Materials and methods. 78 women of reproductive period underwent a complex examination and PMS and PMDD treatment with OC containing 20 mcg of ethinyl estradiol and 3 mg of drospirenone. Results of the study. Analysis of the daily record of severity of problems (DRSP) for 2 months prior treatment showed the presence of moderate PMS in 40 patients (Group I) and severe PMS - PMDD in 38 women (Group II). Group II patients were credibly older than those in Group I. After three months of OC therapy both groups showed a statistically significant reduction in pain syndromes, improved sleep, increased productivity at work, at home, at school and reduced constraints with others. After 6 months of therapy, significant improvements occurred in the psycho-emotional manifestations of PMS (difficulty in concentration, emotional lability, anger, irritation, depression), as well as in physical symptoms (breast tenderness, swelling). Conclusion. Hormonal contraceptives containing drospirenone introduce not only a good contraceptive effect, but can also be used for treatment of both PMS and its most severe form PMDD.